No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 32.1x · 10Y median 118.2x · 2nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:22:22.337Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Janux Therapeutics, Inc. (JANX) stock was $16.78 as of Oct 6, 2026, 3:20 PM EDT, up 1.45% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -31.0% · 3-year avg +17.3%/yr · 5-year avg -6.5%/yr
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies.
Biotechnology · San Diego, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.45
Revenue Est.
$8.03M
Last Quarter Results
EPS
$-0.35
vs Estimate
$-0.29
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1JANX | $1.02B | $16.78 | +1.45% | -30.96% | -6.45% | N/A | N/A |
| 2LMRI | $1.02B | $10.65 | -1.08% | N/A | N/A | N/A | vs JANX |
| 3CSTL | $1.02B | $33.47 | -8.69% | +60.94% | -10.28% | N/A | vs JANX |
| 4IART | $1.03B | $13.24 | -0.38% | -10.16% | -28.16% | -10.66% | vs JANX |
| 5IMTX | $1.01B | $7.51 | -2.79% | -17.69% | -9.88% | N/A | vs JANX |
| 6CGEM | $1.01B | $16.39 | +2.21% | +170.57% | -7.48% | N/A | vs JANX |
forward FY estimate
N/A
$10.27M
vs Estimate
$19.07M
Consensus Rating
Based on 17 analysts
Average Price Target
$36.24
+115.9% upside
Low
$14.00
Current
$16.78
High
$75.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.67 | $-0.47 | $-0.04 | 10 |
| Quarter ending Dec 2026 | $-0.68 | $-0.53 | $-0.39 | 10 |
| Quarter ending Mar 2027 | $-1.28 | $-0.65 | $-0.14 | 8 |
| Quarter ending Jun 2027 | $-1.31 | $-0.66 | $-0.14 | 8 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.14 | $-1.75 | $-1.00 | 12 |
| FY 2027 | $-3.42 | $-2.67 | $-2.09 | 12 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $4.32M | $8.03M | $10.47M | 8 |
| Quarter ending Dec 2026 | $2.88M | $7.29M | $12.79M | 8 |
| Quarter ending Mar 2027 | $1.00M | $2.53M | $4.44M | 4 |
| Quarter ending Jun 2027 | $934054.00 | $2.36M | $4.14M | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $18.98M | $30.07M | $53.66M | 11 |
| FY 2027 | $6.54M | $8.72M | $11.69M | 10 |
